Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23769106 | 0.81 | KCNJ6 (0.46) | NPY1RKMT2A | |
| SCHEMBL27376642 | 0.78 | NPY1R (0.54) | NPY1RNR1I3DRD2NPY2R | |
| SCHEMBL29979364 | 0.77 | NPY1R (0.42) | NPY1R | |
| SCHEMBL25138392 | 0.77 | NPY1R (0.42) | NPY1R | |
| SCHEMBL30806577 | 0.77 | NPY1R (0.51) | NPY1RNR1I3NPY2RL3MBTL1 | |
| SCHEMBL27376880 | 0.77 | NPY1R (0.51) | NPY1RNR1I3NPY2RL3MBTL1 | |
| SCHEMBL23769014 | 0.77 | HDAC6 (0.46) | KMT2AL3MBTL1 | |
| SCHEMBL23769015 | 0.76 | KMT2A (0.50) | KMT2AACHE | |
| SCHEMBL30191291 | 0.76 | ALDH1A1 (0.51) | NPY1RKMT2A | |
| SCHEMBL23769013 | 0.76 | ALDH1A1 (0.51) | NPY1RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | NPY1R 662/4885NR1I3 798/4885DRD2 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.